1628MO A new benchmark for designing phase II trials for advanced or metastatic leiomyosarcoma (LMS) patients using progression free survival (PFS) as primary endpoint – an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) meta-analysis

Authors :: Saskia Litière
W.T.A. van der Graaf
Lorenzo D'Ambrosio
Ian Judson
Anouk Neven
Sandrine Marreaud
Hans Gelderblom
Marta Fiocco
Marie Vinches
Bernd Kasper
Patrick Schöffski
G. Kantidakis
Silvia Stacchiotti
Source :: Annals of Oncology. 31:S977-S978
Publication Year :: 2020
Publisher :: Elsevier BV, 2020.

Subjects :: Oncology
medicine.medical_specialty
business.industry
Soft tissue
Hematology
Bone Sarcoma
Meta-analysis
Internal medicine
Metastatic leiomyosarcoma
Clinical endpoint
medicine
Progression-free survival
business

Tools